NOVARTIS AG-SPONSORED ADR (NVS) Stock Price, Quote, News and Overview
NYSE:NVS - New York Stock Exchange, Inc. - US66987V1098 - ADR
NVS Quote and Key Statistics
NOVARTIS AG-SPONSORED ADR
NYSE:NVS (1/21/2025, 8:17:50 PM)
Premarket: 99.9 +0.17 (+0.17%)99.73
+2.2 (+2.26%)
NVS Financial Highlights
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 35.25% | ||
| ROA | 18.66% | ||
| ROE | 44.37% | ||
| Debt/Equity | 0.47 |
NVS Performance and Technical Analysis
NVS Ownership and Analysts
NVS Latest News and Analysis
Don't overlook NYSE:NVS—it's a hidden gem with strong fundamentals and an attractive price tag.
Investors should take notice ofNOVARTIS AG-SPONSORED ADR (NYSE:NVS)—it offers a great deal for the fundamentals it presents.
Balancing Dividends and Fundamentals: The Case of NYSE:NVS.
Exploring NOVARTIS AG-SPONSORED ADR (NYSE:NVS)'s dividend characteristics.
Google Parent-Owned Startup To Launch AI-Designed Drug Trials By Year-End, Partnering With Eli Lilly And Novartis To Tackle Major Diseases
An Alphabet-backed startup is poised to begin clinical trials of its first artificial intelligence-designed drug by year-end.
JPMorgan's Gori On Trump & 'Incredible' US Economy | Bloomberg The Pulse 01/21
Live from the 2025 World Economic Forum in Davos, we speak to business leaders and central bankers as Donald Trump returns to the White House. JP Morgan's EMEA CEO Filippo Gori says European clients share a split sentiment on the possible outcomes of a second Trump presidency. Also on the show, the Bank of France Governor, Francois Villeroy De Galhau, says the current trend of European disinflation means the ECB may not need to quicken or expand interest rate cuts. Today's guests: Filippo Gori, JP Morgan Chase EMEA CEO & Co-Head of Global Banking; Vas Narasimhan, Novartis CEO; Ron O'Hanley, State Street Chairman & CEO; Francois Villeroy De Galhau, Bank of France Governor (Source: Bloomberg)
Novartis CEO Says Concerns on Trump Health Policy Are Overblown
Moves by the incoming Trump Administration may be a boon to drugmakers, Novartis AG Chief Executive Officer Vas Narasimhan said, while concerns over vaccine policies and public health funding are “overblown.”
US appeals court lifts pause on generic version of Novartis' Entresto
Drugmaker MSN Pharmaceuticals cleared another hurdle on Thursday toward launching its generic version of Novartis' blockbuster heart-failure drug Entresto after a U.S. appeals court ended a temporary pause on MSN's launch. The U.S. Court of Appeals for the District of Columbia Circuit lifted the pause less than 24 hours after it started, potentially freeing MSN to launch its generic in the U.S. amid an ongoing patent dispute between the companies. Spokespeople and an attorney for Novartis did not immediately respond to a request for comment and more information on the ruling.
About NVS
Company Profile
Novartis AG is a holding company, which engages in the business of developing, manufacturing, and marketing healthcare products. The company is headquartered in Basel, Basel-Stadt and currently employs 76,057 full-time employees. The company went IPO on 2001-05-07. The firm develops, manufactures, and markets branded and generic prescription drugs, active pharmaceutical ingredients (APIs), biosimilars and ophthalmic products. The firm uses science and digital technologies for treatments in the disease areas of immunology, dermatology, cancer, ophthalmology, neuroscience, respiratory, cardiovascular, renal and metabolism. The business activities of the Company are divided into two segments: Innovative Medicines, which includes innovative patent-protected prescription medicines for blood pressure, cancer and other ailments, and Sandoz, which includes generic pharmaceuticals and biosimilars.
Company Info
NOVARTIS AG-SPONSORED ADR
Lichtstrasse 35
Basel BASEL-STADT CH 4056 CH
CEO: Vasant (Vas) Narasimhan
Employees: 76057
Company Website: https://www.novartis.com/
Investor Relations: https://www.novartis.com/investors
Phone: 41613241111
NVS Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 72.99 | 704.73B | ||
| NVO | NOVO-NORDISK A/S-SPONS ADR | 27.38 | 359.88B | ||
| JNJ | JOHNSON & JOHNSON | 14.47 | 356.69B | ||
| MRK | MERCK & CO. INC. | 16.17 | 243.45B | ||
| AZN | ASTRAZENECA PLC-SPONS ADR | 17.84 | 210.75B | ||
| PFE | PFIZER INC | 10.33 | 150.97B | ||
| SNY | SANOFI-ADR | 12.43 | 129.60B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 48.75 | 115.69B | ||
| ZTS | ZOETIS INC | 29.09 | 75.58B | ||
| GSK | GSK PLC-SPON ADR | 8.26 | 68.92B | ||
| TAK | TAKEDA PHARMACEUTIC-SP ADR | 21.83 | 41.53B | ||
| TEVA | TEVA PHARMACEUTICAL-SP ADR | 7.85 | 24.72B |